BPC-157 Pricing: September 2026

The price picture as of September 2, 2026. BPC-157 (Body Protection Compound-157) is a synthetic peptide copied from a protein in human stomach fluid, and no regulator has approved it for any human use. Prices have barely moved since our April guide. Research vendors sell a 5 mg vial for about $39 and a 10 mg vial for $48 to $55. A compounding pharmacy, which makes the drug to order for one patient's prescription, charges $75 to $150 for a 5 mg vial. Telehealth programs that bundle the visit, the drug, and shipping start near $199 a month and top out around $350. Insurance covers none of it.

What the July vote did and did not do. On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted 8-6, with one abstention, to recommend BPC-157 for the Section 503A bulks list. That list names the raw ingredients a licensed pharmacy may use when it compounds a drug for a named patient, while Section 503B covers large outsourcing facilities that make batches without patient-specific prescriptions under a separate list. The vote is advice. The FDA still has to publish a proposed rule, take public comments, and issue a final rule before a pharmacy can legally compound BPC-157. Holland & Knight's August 4 legal note said these peptides "still cannot be lawfully compounded," and no proposed rule had appeared by the end of August. Our piece The FDA panel voted yes on BPC-157 and KPV, but compounding is still not legal walks through the remaining steps.

Where clinics stand. The pharmacies and telehealth clinics in the tables below sold compounded BPC-157 before the vote and kept selling it afterward at the same prices, though some clinicians want no part of it. On June 25, 2026, UVA Health obesity medicine director Catherine Varney told WSET she will not prescribe BPC-157 or TB-500 because the evidence comes from animal studies. Abroad, Australia's Therapeutic Goods Administration made unapproved peptides a formal compliance priority in June 2026, with BPC-157 heading its list and import seizures and fines among the tools.

What's next. A second PCAC peptide meeting is due before the end of February 2027, covering five other peptides, GHK-Cu among them; BPC-157's vote is already done. For all six recommended peptides in one place, see Post-PCAC 503A peptide pricing 2026, and for the stack with TB-500, see TB-500 pricing. Research-vendor rows below are for market context only, since those products are labeled research use only and are not for human use.